Diagnostic Efficiency by Gentian - Newsletter H1-2020
14. Jan 2020 |
11 min read
Happy New Year 2020
We look forward to exhibiting at and visiting numerous trade shows and congresses around the world in 2020. You are most welcome to visit our booth to discuss diagnostic efficiency and learn more about our immunoassays at the different events.
If you are based in the US you can meet us at NKF Spring Clinical Meetings(booth #233), AACC (booth #3874) and KidneyWeek (booth #339). We look forward to seeing you there.
For more locations where you can meet the Gentian team and learn more about our products please follow the link below:
Gentian in the US
Gentian USA Inc. was established in 2012. The subsidiary has continuously grown it’s market share for the immunoassays Cystatin C and Canine CRP through routine clients and OEM partners.
In order to expand Gentian’s presence in the USA, we have during 2019, initiated a collaboration with BioHealth Innovation (BHI). The collaboration allows Gentian to support current and new US customers and OEM partners more closely, and will also make our high quality assays more visible to a larger US customer base.
Gentian’s CEO Dr Hilja Ibert, PhD, sat down with BioTalk host Rich Bendis, Founder, President and CEO BioHealth Innovation Inc. In this podcast you can hear Dr Ibert talk about Gentian’s presence in the US market, our biomarkers and how Gentian focuses on innovating diagnostic efficiency.
Calprotectin as a sepsis marker and mortality predictor
The newly published article “Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients” in the Scandinavian Journal of Clinical and Laboratory Investigation describes performance of calprotectin and procalcitonin in differentiation between ICU patients with sepsis and non-sepsis and prediction of 30-day mortality.
The results from the study indicate that calprotectin is superior to procalcitonin as a sepsis biomarker and predictor of 30-day mortality in intensive care patients. This article is based on the same study that was presented at the International Sepsis Forum in Bangkok in 2018
The Gentian Calprotectin Immunoassay
The Gentian Calprotectin Immunoassay is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro diagnostic testing of calprotectin in human plasma samples. The assay is performed in only 10 minutes and can be applied on a wide range of clinical chemistry analysers.